top of page

Meeting Sponsors

Generous support for Relaxin 2023 was provided by the following sponsors:

Logo final_Relaxera_60mm breit.jpg

Relaxera is a pharmaceutical company focused on

  • the development of a treatment of the aging heart (Heart Failure with preserved Ejection Fraction – HFpEF),

  • protecting pancreatic cells against the glucotoxic effects caused by impaired glucose tolerance, and

  • protecting organs in the field of transplantation medicine. 

Our pharmaceutical candidate is synthetic human relaxin-2, the “biological” is well known for its pleiotropic effects in the human body. Relaxera has developed methods for its synthesis in large quantities and is examining its effects on the heart muscle fibres, on the islet cells of pancreas, and selected organs for transplantation.

We have several cooperation projects with research institutes all over the world, e. g. the Heart and Vascular Institute of the University of Pittsburgh, the Division of Transplantation Surgery of the Medical University of Graz, or the Florey Institute of Neuroscience & Mental Health of the University of Melbourne.

We are open for further cooperation projects, contact us via or directly via our website.

Logo ID_36x36mm_600 dpi.jpg
CY petlab_coul.jpg

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Specialist in custom peptide synthesis

Phoenix logofull2.png

B & J Steinetz Charitable Lead Unitrust


Geoffrey Tregear Foundation Fund

bottom of page